Occlusion Balloon vs. 5FR Ureteral Catheter
Recruiting
Occlusion Balloon catheter provides the ability to occlude the exit of the kidney pelvis during percutaneous nephrolithotomy (PCNL) and potentially prevents the migration of stone fragments into the ureter. The necessity for it might be questioned during supine PCNL due to the upward oblique position of the kidney. The objective of the study is to compare the presence of ureteral stone fragments upon completion of supine PCNL with and without using an occlusion balloon catheter (OBC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/23/2025
Locations: Mount Sinai West, New York, New York
Conditions: Kidney Stones
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-type Cyclins or Amplification of CDK4 or CDK6
Recruiting
This research study is studying a targeted therapy as a possible treatment for cancer abnormality in one of the following genes: CCND1, CCND2, CCND3, CDK4, or CDK6. The drug involved in this study is: -Abemaciclib
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/23/2025
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Cancer
Optimizing Family Counseling for Anticipated Extremely Preterm Delivery
Recruiting
Antenatal family counseling for anticipated extremely preterm deliveries remains ethically and practically challenging for maternal-fetal medicine specialists and neonatologists alike. The overall goal of this project is to improve antenatal counseling and counseling outcomes for families facing anticipated extremely preterm delivery through innovative, interdisciplinary simulation-based education for maternal fetal medicine specialists and neonatologists, using language preferred by families, a... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
01/23/2025
Locations: Boston Children's Hosptial, Boston, Massachusetts +2 locations
Conditions: Preterm Pregnancy, Premature Birth
Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma
Recruiting
This is a single-institution, single-arm, phase 2 study in which belantamab mafodotin (GSK2857916), an antibody-drug conjugate targeting B-cell maturation antigen (BCMA), will be administered to patients with multiple myeloma prior to and following high-dose melphalan and autologous stem cell transplantation (ASCT), in conjunction with standard lenalidomide maintenance. We hypothesize that administration of belantamab mafodotin as part of autologous stem cell transplant consolidation and mainten... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/23/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Myeloma
An Imaging Technology, Contrast-Enhanced Mammography, in Predicting Breast Cancer
Recruiting
This clinical trial examines a new imaging technology, contrast-enhanced mammography, in predicting breast cancer. Contrast-enhanced mammography is similar to standard mammography, but it includes an intravenous (by vein) injection of iodine-based contrast, which makes tissue and blood vessels more visible in scans. Contrast-enhanced mammography may work better in detecting cancer in the breast that is not seen on other imaging tests and may help doctors find the most suspicious areas of the bre... Read More
Gender:
ALL
Ages:
Between 25 years and 85 years
Trial Updated:
01/23/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Breast Carcinoma
Exercise to Enhance Cardiovascular Health Among Black Prostate Cancer Patients With Androgen Deprivation Therapy
Recruiting
The purpose of this research is to determine whether a 16-week culturally tailored, technology-based, aerobic and resistance exercise intervention improves cardiovascular risk factors in Black men diagnosed with prostate cancer and are undergoing androgen deprivation therapy (ADT), and whether it will also improve physical fitness and function, body composition, and outcomes such as quality of life, cancer symptoms, and self-esteem. Participants in this study will be randomly assigned to one of... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
01/23/2025
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Androgen Deprivation Therapy, Prostate Cancer, Prostate Cancer Metastatic
MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma
Recruiting
In this first-in human, phase I/IIa study, the safety and efficacy of \[212Pb\]VMT01, an alpha-particle emitting therapeutic agent targeted to melanocortin sub-type 1 receptor (MC1R) is being evaluated as a monotherapy and in combination with Nivolumab in subjects with unresectable and metastatic melanoma.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
01/23/2025
Locations: Biogenix Molecular, Miami, Florida +9 locations
Conditions: Melanoma (Skin), Metastatic Melanoma, Melanoma Stage IV, Mucosal Melanoma, Melanoma Stage III
A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial
Recruiting
This is to study if neoadjuvant atezolizumab therapy is beneficial for patients with recurrent glioblastoma and a low mutational burden.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/23/2025
Locations: Saint Luke's Cancer Institute, Kansas City, Missouri +2 locations
Conditions: Recurrent Glioblastoma
Psilocybin for Major Depressive Disorder (MDD)
Recruiting
Approximately 240 eligible adult participants (≥18 years old) who meet Diagnostic and Statistical Manual of Mental Disorders (DSM-5-TR) criteria for Major Depressive Disorder (MDD) will be enrolled. Participants will be randomly assigned to receive a single oral dose of Psilocybin 25 mg, Psilocybin 5 mg, or inactive placebo. The purpose of this study is to evaluate the efficacy, safety, and tolerability of Psilocybin 25 mg versus placebo in adults with MDD, as assessed by the difference between... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/23/2025
Locations: University of Alabama Clinical Research Unit, Birmingham, Alabama +25 locations
Conditions: Depressive Disorder, Major
Juveena Hydrogel System Feasibility Study for Heavy Menstrual Bleeding (HMB)
Recruiting
This is a prospective, multicenter, single-arm interventional feasibility study to evaluate the safety and feasibility of the Juveena Hydrogel System for temporary control of heavy menstrual bleeding (HMB) in women with a history of chronic ovulatory HMB.
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
01/23/2025
Locations: Arizona Gynecology Consultants, Phoenix, Arizona
Conditions: Heavy Menstrual Bleeding
Brain Health Fitness Program: Exercise for People with Mild-moderate Cognitive Impairments
Recruiting
The goal of this clinical trial is to test a 6-month, twice a week, moderate intensity exercise and coaching program (an in-person group and a distance group) for adults with mild-moderate cognitive impairments living in South Carolina. The main questions it aims to answer are: 1. Is the program practical to conduct, and it is acceptable and enjoyable? The hypothesis is that it will be possible to recruit participants, obtain the desired dosage of moderate intensity fitness and strength trainin... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/23/2025
Locations: Arnold School of Public Health, Columbia, South Carolina
Conditions: Cognitive Impairment
Language in Primary Progressive Aphasia
Recruiting
The purpose of this study is to further define the neurological and linguistic deterioration in primary progressive aphasia.
Gender:
ALL
Ages:
All
Trial Updated:
01/23/2025
Locations: Northwestern University, Chicago, Illinois
Conditions: Primary Progressive Aphasia